Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

Kurtzke, J. F. (1983) · Neurology · doi:10.1212/wnl.33.11.1444 · Cited by 15,011

New diagnostic criteria for multiple sclerosis: Guidelines for research protocols

Poser, C. M., Paty, D. W., Scheinberg, L., McDonald, W. I., Davis, F. A., Ebers, G. C., Johnson, K. P., Sibley, W. A., Silberberg, D. H., & Tourtellotte, W. W. (1983) · Annals of Neurology · doi:10.1002/ana.410130302 · Cited by 7,384

Defining the clinical course of multiple sclerosis

LUBLIN, F. D., & Reingold, S. C. (1996) · Neurology · doi:10.1212/wnl.46.4.907 · Cited by 3,762

Generalized Linear Models

Schuenemeyer, J. H., McCullagh, P. J., & Nelder, J. A. (1992) · Technometrics · doi:10.2307/1269238 · Cited by 2,702

Interferon beta‐lb in the treatment of multiple sclerosis

The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group (1995) · Neurology · doi:10.1212/wnl.45.7.1277 · Cited by 971

The role of magnetic resonance techniques in understanding and managing multiple sclerosis

Miller, D. (1998) · Brain · doi:10.1093/brain/121.1.3 · Cited by 553

Inflammatory central nervous system demyelination: Correlation of magnetic resonance imaging findings with lesion pathology

Brück, W., Bitsch, A., Kolenda, H., Brück, Y., Stiefel, M., & Lassmann, H. (1997) · Annals of Neurology · doi:10.1002/ana.410420515 · Cited by 520

The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up

O’Riordan, J. I. (1998) · Brain · doi:10.1093/brain/121.3.495 · Cited by 480

Accumulation of hypointense lesions ("black holes") on T 1 spin-echo MRI correlates with disease progression in multiple sclerosis

Truyen, L., van Waesberghe, J. H. T. M., van Walderveen, M. A. A., van Oosten, B. W., Polman, C. H., Hommes, O. R., Adèr, H. J., & Barkhof, F. (1996) · Neurology · doi:10.1212/wnl.47.6.1469 · Cited by 461

Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis

Katz, D., Taubenberger, J. K., Cannella, B., McFarlin, D. E., Raine, C. S., & McFarland, H. F. (1993) · Annals of Neurology · doi:10.1002/ana.410340507 · Cited by 387

Quantification of multiple-sclerosis-related brain atrophy in two heterogeneous MRI datasets using mixed-effects modeling

Jones, B. C., Nair, G., Shea, C. D., Crainiceanu, C. M., Cortese, I. C. M., & Reich, D. S. (2013) · NeuroImage Clinical · doi:10.1016/j.nicl.2013.08.001 · Cited by 34

Visualisation of the kinetics of macrophage infiltration during experimental autoimmune encephalomyelitis by magnetic resonance imaging

Baeten, K., Hendriks, J. J. A., Hellings, N., Theunissen, E., Vanderlocht, J., Ryck, L. D., Gelan, J., Stinissen, P., & Adriaensens, P. (2008) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2007.11.008 · Cited by 34

Disease-modifying therapies for multiple sclerosis

Corboy, J. R., Goodin, D. S., & Frohman, E. M. (2003) · Current Treatment Options in Neurology · doi:10.1007/s11940-003-0021-0 · Cited by 33

Magnetization transfer magnetic resonance imaging and clinical changes in patients with relapsing-remitting multiple sclerosis.

Oreja-Guevara, C., Charil, A., Caputo, D., Cavarretta, R., Sormani, M., & Filippi, M. (2006) · Archives of Neurology · doi:10.1001/archneur.63.5.736 · Cited by 34

Nanomedicine in cerebral palsy

Kannan, S., Balakrishnan, B., Nance, E., Johnston, M., & Rangaramanujam, K. (2013) · International Journal of Nanomedicine · doi:10.2147/ijn.s35979 · Cited by 33

Clinical and conventional MRI predictors of disability and brain atrophy accumulation in RRMS

Mesaroš, Š., Rocca, M. A., Sormani, M. P., Charil, A., Comi, G., & Filippi, M. (2008) · Journal of Neurology · doi:10.1007/s00415-008-0924-5 · Cited by 33

Diagnosis and Management of Secondary-Progressive Multiple Sclerosis: Time for Change

Oh, J., Alikhani, K., Bruno, T. R., Devonshire, V. A., Giacomini, P. S., Giuliani, F., Nakhai-Pour, H. R., Schecter, R., & Larochelle, C. (2019) · Neurodegenerative Disease Management · doi:10.2217/nmt-2019-0024 · Cited by 34

Pirfenidone for chronic progressive multiple sclerosis

Walker, J. E., & Margolin, S. B. (2001) · Multiple Sclerosis Journal · doi:10.1177/135245850100700506 · Cited by 33

Systematic review of immunomodulatory drugs for the treatment of people with multiple sclerosis: Is there good quality evidence on effectiveness and cost?

Bryant, J. (2001) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.70.5.574 · Cited by 33

Effects of seasons on magnetic resonance imaging–measured disease activity in patients with multiple sclerosis

Rovaris, M., Comı, G., Sormani, M. P., Wolinsky, J. S., Ladkani, D., & Filippi, M. (2001) · Annals of Neurology · doi:10.1002/ana.83 · Cited by 33

MRI outcomes in the diagnosis and disease course of multiple sclerosis

Simon, J. H. (2014) · Handbook of clinical neurology · doi:10.1016/b978-0-444-52001-2.00017-0 · Cited by 33

Immunomodulatory drugs for multiple sclerosis: a systematic review of clinical and cost effectiveness

Clegg, A. J., & Bryant, J. (2001) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2.4.623 · Cited by 32

Serial contrast-enhanced magnetic resonance imaging and spectroscopic imaging of acute multiple sclerosis lesions under high-dose methylprednisolone therapy

Schocke, M. F. H., Berger, T., Felber, S. R., Wolf, C., Deisenhammer, F., Kremser, C., Seppi, K., & Aichner, F. (2003) · NeuroImage · doi:10.1016/s1053-8119(03)00409-9 · Cited by 32

High-dose, frequently administered interferon beta therapy for relapsing–remitting multiple sclerosis must be maintained over the long term: the interferon beta dose-reduction study

Barbero, P., Verdun, E., Bergui, M., Pipieri, A., Clerico, M., Cucci, A., Ricci, A., Bergamasco, B., & Durelli, L. (2004) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2004.03.023 · Cited by 32

Magnetic Resonance Imaging of Multiple Sclerosis

Filippi, M., Tortorella, C., & Rovaris, M. (2002) · Journal of Neuroimaging · doi:10.1111/j.1552-6569.2002.tb00136.x · Cited by 33

Multiple sclerosis: Inflammation, autoimmunity and plasticity

Bassi, M. S., Iezzi, E., & Centonze, D. (2022) · Handbook of clinical neurology · doi:10.1016/b978-0-12-819410-2.00024-2 · Cited by 34

The predictive value of gadolinium enhancement for long term disability in relapsing-remitting multiple sclerosis-preliminary results

Losseff, N. A., Miller, D. H., Kidd, D. P., & Thompson, A. J. (2001) · Multiple Sclerosis Journal · doi:10.1177/135245850100700105 · Cited by 31

Recombinant Erythropoietin Down-Regulates IL-6 and CXCR4 Genes in TNF-α-Treated Primary Cultures of Human Microvascular Endothelial Cells: Implications for Multiple Sclerosis

Avasarala, J., & Sastry, K. S. (2005) · Journal of Molecular Neuroscience · doi:10.1385/jmn:25:2:183 · Cited by 29

Quantitative electroencephalography reveals different physiological profiles between benign and remitting-relapsing multiple sclerosis patients

Vázquez-Marrufo, M., González-Rosa, J. J., Vaquero, E., Duque, P., Borges, M., Gómez, C. M., & Izquierdo, G. (2008) · BMC Neurology · doi:10.1186/1471-2377-8-44 · Cited by 28

Brain atrophy as a surrogate marker in MS

Jagust, W. J., & Noseworthy, J. H. (2000) · Neurology · doi:10.1212/wnl.54.4.782 · Cited by 28

Natural History of Multiple Sclerosis: Early Prognostic Factors

Mowry, E. M. (2011) · Neurologic Clinics · doi:10.1016/j.ncl.2011.01.001 · Cited by 27

Thickness of retinal nerve fiber layer correlates with disease duration

Spain, R., Maltenfort, M., Sergott, R. C., & Leist, T. P. (2009) · The Journal of Rehabilitation Research and Development · doi:10.1682/jrrd.2008.11.0156 · Cited by 27

The relation between MRI measures of inflammation and neurodegeneration in multiple sclerosis

Inglese, M., Benedetti, B., & Filippi, M. (2005) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2005.03.001 · Cited by 27

Neuroimaging in Multiple Sclerosis: Neurotherapeutic Implications

Sicotte, N. L. (2011) · Neurotherapeutics · doi:10.1007/s13311-010-0008-y · Cited by 26

Incidental demyelinating inflammatory lesions in asymptomatic patients: a Brazilian cohort with radiologically isolated syndrome and a critical review of current literature

Maia, A. C. M., da Rocha, A. J., Barros, B. R., & Tilbery, C. P. (2012) · Arquivos de Neuro-Psiquiatria · doi:10.1590/s0004-282x2012000100003 · Cited by 28

Dimethyl fumarate: a Janus-faced substance?

Kees, F. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.804912 · Cited by 26

CONTRAST ENHANCEMENT AND THE ACUTE LESION IN MULTIPLE SCLEROSIS

Rovaris, M., & Filippi, M. (2000) · Neuroimaging Clinics of North America · doi:10.1016/s1052-5149(25)00669-0 · Cited by 26

Is Gadolinium Enhancement Predictive of the Development of Brain Atrophy in Multiple Sclerosis? A Review of the Literature

Zivadinov, R., & Zorzon, M. (2002) · Journal of Neuroimaging · doi:10.1111/j.1552-6569.2002.tb00137.x · Cited by 26

Optical coherence tomography should be part of the routine monitoring of patients with multiple sclerosis: Yes

Saidha, S., & Calabresi, P. A. (2014) · Multiple Sclerosis Journal · doi:10.1177/1352458514541509 · Cited by 25

Applications of nanotechnology in molecular imaging of the brain

McAteer, M. A., & Choudhury, R. P. (2009) · Progress in brain research · doi:10.1016/s0079-6123(08)80004-0 · Cited by 25

Consensus guidelines for the diagnosis and treatment of multiple sclerosis

Yamout, B., Alroughani, R., Al-Jumah, M., Khoury, S., Abouzeid, N., Dahdaleh, M., Alsharoqi, I., Inshasi, J., Hashem, S., Zakaria, M., et al. (2013) · Current Medical Research and Opinion · doi:10.1185/03007995.2013.787979 · Cited by 25

Brain Lesion Volume and Neuropsychological Function Predict Efficacy of Treatment for Depression in Multiple Sclerosis.

Mohr, D. C., Epstein, L. A., Luks, T. L., Goodkin, D. E., Cox, D., Goldberg, A., Chin, C. T., & Nelson, S. J. (2003) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.71.6.1017 · Cited by 25

Inversion recovery ultrashort echo time imaging of ultrashort T2 tissue components in ovine brain at 3 T: a sequential D2O exchange study

Fan, S., Ma, Y., Chang, E. Y., Bydder, G. M., & Du, J. (2017) · NMR in Biomedicine · doi:10.1002/nbm.3767 · Cited by 25

Monthly brain magnetic resonance imaging scans in patients with clinically isolated syndrome

Pestalozza, I. F., Pozzilli, C., Legge, S. D., Piattella, M. C., Pantano, P., Caramia, F., Pasqualetti, P., & Lenzi, G. L. (2005) · Multiple Sclerosis Journal · doi:10.1191/1352458505ms1175oa · Cited by 25

Novel composite MRI scale correlates highly with disability in multiple sclerosis patients

Kosa, P. F., Komori, M., Waters, R. S., Wu, T., Cortese, I. C. M., Ohayon, J. M., Fenton, K. M., Cherup, J., Gedeon, T., & Bielekova, B. (2015) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2015.08.009 · Cited by 25

Multiple sclerosis lesions: insights from imaging techniques

Tomassini, V., & Palace, J. A. (2009) · Expert Review of Neurotherapeutics · doi:10.1586/ern.09.83 · Cited by 25

A comparison of the sensitivity of MRI after double- and triple-dose Gd-DTPA for detecting enhancing lesions in multiple sclerosis☆

Gasperini, C., Paolillo, A., Rovaris, M., Yousry, T. A., Capra, R., Bastianello, S., & Filippi, M. (2000) · Magnetic Resonance Imaging · doi:10.1016/s0730-725x(00)00156-9 · Cited by 25

Increased contrast enhancing lesion activity in relapsing–remitting multiple sclerosis migraine patients

Graziano, E. J., Hagemeier, J., Weinstock‐Guttman, B., Ramasamy, D. P., & Zivadinov, R. (2015) · NeuroImage Clinical · doi:10.1016/j.nicl.2015.07.013 · Cited by 24

Insights from magnetic resonance imaging

Filippi, M., Charil, A., Rovaris, M., Absinta, M., & Rocca, M. A. (2014) · Handbook of clinical neurology · doi:10.1016/b978-0-444-52001-2.00006-6 · Cited by 26

Review of the clinical evidence for interferon β 1a (Rebif®) in the treatment of multiple sclerosis

Monzani, F. (2008) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s476 · Cited by 24

Multiple sclerosis trial designs for the 21st century: Building on recent lessons

LUBLIN, F. D. (2005) · Journal of Neurology · doi:10.1007/s00415-005-5008-1 · Cited by 24

Magnetic Resonance Imaging in Multiple Sclerosis – Patients' Experiences, Information Interests and Responses to an Education Programme

Brand, J. S., Köpke, S., Kasper, J., Rahn, A. C., Backhus, I., Poettgen, J., Stellmann, J., Gellißen, S., & Heesen, C. (2014) · PLoS ONE · doi:10.1371/journal.pone.0113252 · Cited by 23

MRI criteria in MS patients with negative and positive oligoclonal bands: equal fulfillment of Barkhof’s criteria but different lesion patterns

Huttner, H. B., Schellinger, P. D., Struffert, T., Richter, G., Engelhorn, T., Bassemir, T., Mäurer, M., Garcia, M., Schwab, S., Köhrmann, M., et al. (2009) · Journal of Neurology · doi:10.1007/s00415-009-5081-y · Cited by 23

Vascular Disease in Patients with Multiple Sclerosis: A Review

Caprio, M. G., & Russo, C. (2016) · Journal of Vascular Medicine & Surgery · doi:10.4172/2329-6925.1000259 · Cited by 22

MRI monitoring of MS in clinical trials

Miller, D. H. (2002) · Clinical Neurology and Neurosurgery · doi:10.1016/s0303-8467(02)00045-8 · Cited by 23

Ocrelizumab in Early-Stage Relapsing-Remitting Multiple Sclerosis

Hartung, H., Benedict, R. H. B., Berger, T., Bermel, R. A., Brochet, B., Carroll, W. M., Freedman, M. S., Holmøy, T., Karabudak, R., Nos, C., et al. (2024) · Neurology · doi:10.1212/wnl.0000000000210049 · Cited by 22

Discontinuation of disease-modifying therapy in MS patients over 60 years old and its impact on relapse rate and disease progression

Salavisa, M., Serrazina, F., Ladeira, F. F., & Correia, A. S. (2023) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2023.107612 · Cited by 22

Reviewing the Unmet Needs of Patients with Multiple Sclerosis.

Mehr, S. R., & Zimmerman, M. P. (2015) · Europe PMC (PubMed Central) · Cited by 22

Multiple Sclerosis

Sommer, N. N., Saam, T., Coppenrath, E., Kooijman, H., Kümpfel, T., Patzig, M., Beyer, S. E., Sommer, W. H., Reiser, M. F., Ertl-Wagner, B. B., et al. (2017) · Investigative Radiology · doi:10.1097/rli.0000000000000410 · Cited by 22

Macular Ganglion Cell and Inner Plexiform Layer Thickness Is More Strongly Associated With Visual Function in Multiple Sclerosis Than Bruch Membrane Opening–Minimum Rim Width or Peripapillary Retinal Nerve Fiber Layer Thicknesses

Nguyen, J. V., Rothman, A., Gonzalez, N., Avornu, A., Ogbuokiri, E., Balcer, L. J., Galetta, S. L., Frohman, E. M., Frohman, T. C., Crainiceanu, C. M., et al. (2019) · Journal of Neuro-Ophthalmology · doi:10.1097/wno.0000000000000768 · Cited by 22

Prognostic relevance of MRI in early relapsing multiple sclerosis: ready to guide treatment decision making?

Hoffmann, O. M., Gold, R., Meuth, S. G., Linker, R. A., Skripuletz, T., Wiendl, H., & Wattjes, M. P. (2024) · Therapeutic Advances in Neurological Disorders · doi:10.1177/17562864241229325 · Cited by 24

Mediators of apoptosis Fas and FasL predict disability progression in multiple sclerosis over a period of 10 years

Lopatinskaya, L., Zwemmer, J., Uitdehaag, B. M. J., Lucas, K., Polman, C. H., & Nagelkerken, L. M. (2006) · Multiple Sclerosis Journal · doi:10.1177/1352458506070826 · Cited by 21

Thermal neutron detector based on COTS CMOS imagers and a conversion layer containing Gadolinium

Pérez, M., Blostein, J. J., Bessia, F. A., Tartaglione, A., Sidelnik, I., Sofo-Haro, M., Suárez, S., Gimenez, M. L., Berisso, M. G., & Lipovetzky, J. (2018) · Nuclear Instruments and Methods in Physics Research Section A Accelerators Spectrometers Detectors and Associated Equipment · doi:10.1016/j.nima.2018.03.032 · Cited by 20

Efficient segmentation of active and inactive plaques in FLAIR-images using DeepLabV3Plus SE with efficientnetb0 backbone in multiple sclerosis

Davarani, M. N., Darestani, A. A., Guillén, V., Azimi, H., Havadaragh, S. H., Hashemi, H., & Harirchian, M. H. (2024) · Scientific Reports · doi:10.1038/s41598-024-67130-6 · Cited by 22

Multiple sclerosis

Filippi, M., Preziosa, P., & Rocca, M. A. (2016) · Handbook of clinical neurology · doi:10.1016/b978-0-444-53485-9.00020-9 · Cited by 21

Treatment of internuclear ophthalmoparesis in multiple sclerosis with fampridine: A randomized double‐blind, placebo‐controlled cross‐over trial

Kanhai, K. M. S., Bijvank, J. A. N., Wagenaar, Y. L., Klaassen, E. S., Lim, K. Y., Bergheanu, S. C., Petzold, A., Verma, A., Hesterman, J. Y., Wattjes, M. P., et al. (2019) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13096 · Cited by 20

Inversion Recovery Ultrashort TE MR Imaging of Myelin is Significantly Correlated with Disability in Patients with Multiple Sclerosis

Jang, H., Ma, Y., Chang, E. Y., Dehkordy, S. F., Lee, R. R., Lombardi, A. F., Bydder, G. M., Corey‐Bloom, J., & Du, J. (2021) · American Journal of Neuroradiology · doi:10.3174/ajnr.a7006 · Cited by 20

T2 hypointense rims and ring-enhancing lesions in MS

Llufriú, S., Pujol, T., Blanco, Y., Hankiewicz, K., Squarcia, M., Berenguer, J., Villoslada, P., Graus, F., & Saiz, A. (2010) · Multiple Sclerosis Journal · doi:10.1177/1352458510377905 · Cited by 20

MRI aspects of the ?inflammatory phase? of multiple sclerosis

Filippi, M., & Rocca, M. A. (2003) · Neurological Sciences · doi:10.1007/s10072-003-0173-4 · Cited by 20

Single-timepoint low-dimensional characterization and classification of acute versus chronic multiple sclerosis lesions using machine learning

Caba, B., Cafaro, A., Lombard, A., Arnold, D. L., Elliott, C., Liu, D., Jiang, X., Gafson, A., Fisher, E., Belachew, S. M., et al. (2022) · NeuroImage · doi:10.1016/j.neuroimage.2022.119787 · Cited by 20

AI-based detection of contrast-enhancing MRI lesions in patients with multiple sclerosis

Schlaeger, S., Shit, S., Eichinger, P., Hamann, M., Opfer, R., Krüger, J., Dieckmeyer, M., Schön, S., Mühlau, M., Zimmer, C., et al. (2023) · Insights into Imaging · doi:10.1186/s13244-023-01460-3 · Cited by 22

Cervical cord magnetization transfer ratio and clinical changes over 18 months in patients with relapsing-remitting multiple sclerosis: a preliminary study

Charil, A., Caputo, D., Cavarretta, R., Sormani, M. P., Ferrante, P., & Filippi, M. (2006) · Multiple Sclerosis Journal · doi:10.1177/1352458506070714 · Cited by 19

Cumulative Dose of Macrocyclic Gadolinium-Based Contrast Agent Improves Detection of Enhancing Lesions in Patients with Multiple Sclerosis

Rovira, À., Auger, C., Huerga, E. C., Corral, J. F., Mitjana, R., Sastre‐Garriga, J., Tintoré, M., & Montalbán, X. (2017) · American Journal of Neuroradiology · doi:10.3174/ajnr.a5253 · Cited by 19

Three subsequent single doses of gadolinium chelate for brain MR imaging in multiple sclerosis.

Sardanelli, F., Iozzelli, A., Losacco, C., Murialdo, A., & Filippi, M. (2003) · PubMed Central · Cited by 19

Heterogeneity in Response to Interferon Beta in Patients With Multiple Sclerosis

Chiu, A. W. (2008) · Archives of Neurology · doi:10.1001/archneur.66.1.noc80047 · Cited by 19

Magnetic Resonance Imaging Advances in Multiple Sclerosis

Bakshi, R. (2005) · Journal of Neuroimaging · doi:10.1177/1051228405283362 · Cited by 19

Does interferon beta help in secondary progressive MS?

Cohen, J. A., & Antel, J. P. (2004) · Neurology · doi:10.1212/01.wnl.0000147171.32178.48 · Cited by 19

Magnetic Resonance Imaging in Multiple Sclerosis

Neema, M., Ceccarelli, A., Jackson, J. S., & Bakshi, R. (2012) · Wiley eBooks · doi:10.1002/9781119963714.ch6 · Cited by 19

Assessing treatment response to oral drugs for multiple sclerosis in real-world setting: a MAGNIMS Study

Ruggieri, S., Prosperini, L., Al‐Araji, S., Annovazzi, P. O. L., Bisecco, A., Ciccarelli, O., Stefano, N. D., Filippi, M., Fleischer, V., Evangelou, N., et al. (2023) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2023-331920 · Cited by 18

MRI relapses have significant pathologic and clinical implications in multiple sclerosis

Traboulsee, A. L. (2007) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2007.01.064 · Cited by 18

Selecting a disease-modifying agent as platform therapy in the long-term management of multiple sclerosis

Stuart, W. H., COHAN, S. L., Richert, J. R., & Achiron, A. (2004) · Neurology · doi:10.1212/wnl.63.11_suppl_5.s19 · Cited by 18

Flow cytometric analysis of T cell/monocyte ratio in clinically isolated syndrome identifies patients at risk of rapid disease progression

Nemecek, A., Zimmermann, H., Rübenthaler, J., Fleischer, V., Paterka, M., Luessi, F., Müller‐Forell, W., Zipp, F., & Siffrin, V. (2015) · Multiple Sclerosis Journal · doi:10.1177/1352458515593821 · Cited by 17

Regression to the Mean and Predictors of MRI Disease Activity in RRMS Placebo Cohorts - Is There a Place for Baseline-to-Treatment Studies in MS?

Stellmann, J., Stürner, K. H., Young, K. L., Gellißen, S., Friede, T., & Heesen, C. (2015) · PLoS ONE · doi:10.1371/journal.pone.0116559 · Cited by 17

MRI in Multiple Sclerosis

Simon, J. H. (2005) · Physical Medicine and Rehabilitation Clinics of North America · doi:10.1016/j.pmr.2005.01.012 · Cited by 17

Currently approved and emerging oral therapies in multiple sclerosis: An update for the ophthalmologist

Eckstein, C. P., & Bhatti, M. T. (2015) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2015.12.001 · Cited by 21

Evaluation of Normal Appearing White Matter in Multiple Sclerosis

Yonca Akgoz, A. N. I. K., Demırcı, A., Efendi, H., Bulut, S. S. D., Çelebi, İ., & Komsuoğlu, S. Ş. (2011) · Clinical Neuroradiology · doi:10.1007/s00062-011-0091-4 · Cited by 17

One year activity on subtraction MRI predicts subsequent 4 year activity and progression in multiple sclerosis

Liguori, M., Meier, D., Hildenbrand, P. G., Healy, B. C., Chitnis, T., Baruch, N., Khoury, S. J., Weiner, H. L., Bakshi, R., Barkhof, F., et al. (2011) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2011.242115 · Cited by 17

Efficacy and Safety of Oral Therapies for Relapsing-Remitting Multiple Sclerosis

Paolicelli, D., Manni, A., Iaffaldano, A., & Trojano, M. (2020) · CNS Drugs · doi:10.1007/s40263-019-00691-7 · Cited by 17

Evaluation of the effects of a new drug candidate (GEMSP) in a chronic EAE model

Mangas, A., Coveñas, R., Bodet, D., León, M. A. D., Duleu, S., & Geffard, M. (2008) · International Journal of Biological Sciences · doi:10.7150/ijbs.4.150 · Cited by 17

MRI predictors for the conversion from contrast-enhancing to iron rim multiple sclerosis lesions

Wenzel, N., Wittayer, M., Weber, C. E., Schirmer, L., Platten, M., Gass, A., & Eisele, P. (2022) · Journal of Neurology · doi:10.1007/s00415-022-11082-2 · Cited by 16

Monocyte activation and disease activity in multiple sclerosis. A longitudinal analysis of serum MRP8/14 levels

Floris, S., van der Goes, A., Killestein, J., Knol, D. L., Barkhof, F., Polman, C. H., Dijkstra, C. D., de Vries, H. E., & Meilof, J. F. (2004) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2003.11.005 · Cited by 16

The Use of MR Imaging as an Outcome Measure in Multiple Sclerosis Clinical Trials

Bermel, R. A., Fisher, E., & Cohen, J. A. (2008) · Neuroimaging Clinics of North America · doi:10.1016/j.nic.2008.06.008 · Cited by 16

Magnetic resonance-based techniques for the study and management of multiple sclerosis

Rovaris, M., Rocca, M. A., & Filippi, M. (2003) · British Medical Bulletin · doi:10.1093/bmb/65.1.133 · Cited by 16

Mitoxantrone in multiple sclerosis.

Neuhaus, O., Kieseier, B. C., & Hartung, H. (2006) · PubMed · Cited by 16

Sample size estimations for MRI-monitored trials of MS comparing new vs standard treatments

Sormani, M. P., Rovaris, M., Bagnato, F. R., Molyneux, P. D., Bruzzi, P., Pozzilli, C., Miller, D., Comi, G., & Filippi, M. (2001) · Neurology · doi:10.1212/wnl.57.10.1883 · Cited by 16

Follicle on the Roof: Tertiary Lymphoid Structures in Central Nervous System Autoimmunity

Zuo, M., Wang, A. A., & Gommerman, J. L. (2025) · Immunological Reviews · doi:10.1111/imr.70045 · Cited by 16

Clinical and immune responses correlate in glatiramer acetate therapy of multiple sclerosis

Cavelti‐Weder, C., Baltariu, G. M., Wyler, K., Gober, H. J., Lienert, C., Schluep, M., Radue, E. W., Libero, G. D., Kappos, L., & Duda, P. W. (2005) · European Journal of Neurology · doi:10.1111/j.1468-1331.2005.01084.x · Cited by 15

Can clinical outcomes be used to detect neuroprotection in multiple sclerosis?

Khan, O. (2007) · Neurology · doi:10.1212/01.wnl.0000275235.43506.d2 · Cited by 15

Declaration of Helsinki should be strengthened. Equipoise is essential principle of human experimentation.

Milne, R., Clegg, A., & Bryant, J. (2001) · PubMed Central · Cited by 15

Therapeutic strategies in multiple sclerosis. I. Immunotherapy

Hohlfeldf, R. (1999) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.1999.0513 · Cited by 15

Measuring disability in relapsing-remitting MS

Rudick, R. A., & Kappos, L. (2010) · Neurology · doi:10.1212/wnl.0b013e3181ecf815 · Cited by 14

Interferon β treatment in relapsing–remitting multiple sclerosis. A review

Grigoriadis, N. (2002) · Clinical Neurology and Neurosurgery · doi:10.1016/s0303-8467(02)00048-3 · Cited by 14

Magnetic resonance imaging techniques to define and monitor tissue damage and repair in multiple sclerosis

Filippi, M., & Rocca, M. A. (2007) · Journal of Neurology · doi:10.1007/s00415-007-1010-0 · Cited by 14

The OPTimization of Interferon for MS Study: 375 μg interferon beta-1b in suboptimal responders

Durelli, L., Barbero, P., Bergui, M., Versino, E., Bassano, M. A., Verdun, E., Ferrero, B., Rivoiro, C., Ferrero, C., Picco, E., et al. (2008) · Journal of Neurology · doi:10.1007/s00415-008-0879-6 · Cited by 14

Neuroimaging in multiple sclerosis

Traboulsee, A. L., Zhao, G., & Li, D. K. B. (2005) · Neurologic Clinics · doi:10.1016/j.ncl.2004.10.001 · Cited by 14

Contemporary Immunomodulatory Therapy for Multiple Sclerosis

Rudick, R. A. (2001) · Journal of Neuro-Ophthalmology · doi:10.1097/00041327-200112000-00012 · Cited by 14

Magnetic resonance imaging prognostic factors for survival and relapse in dogs with meningoencephalitis of unknown origin

Gonçalves, R., Decker, S. D., Walmsley, G., & Maddox, T. W. (2024) · Frontiers in Veterinary Science · doi:10.3389/fvets.2024.1370882 · Cited by 13

Imaging biomarkers in multiple Sclerosis: From image analysis to population imaging

Barillot, C., Edan, G., & Commowick, O. (2016) · Medical Image Analysis · doi:10.1016/j.media.2016.06.017 · Cited by 13

Silent lesions on MRI imaging – Shifting goal posts for treatment decisions in multiple sclerosis

Min, M., Spelman, T. D., Lugaresi, A., Boz, C., Spitaleri, D. L. A., Pucci, E., Grand’Maison, F., Granella, F., Izquierdo, G., Butzkueven, H., et al. (2018) · Multiple Sclerosis Journal · doi:10.1177/1352458518798147 · Cited by 13

Blood-brain barrier permeability changes in the first year after alemtuzumab treatment predict 2-year outcomes in relapsing-remitting multiple sclerosis

Knudsen, M. H., Lindberg, U., Frederiksen, J. L., Vestergaard, M. B., Simonsen, H. J., Varatharaj, A., Galea, I., Blinkenberg, M., Sellebjerg, F. T., Larsson, H. B. W., et al. (2022) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2022.103891 · Cited by 13

Gadolinium enhanced MRI predicts clinical and MRI disease activity in relapsing-remitting multiple sclerosis.

Koudriavtseva, T., Thompson, A. J., Fiorelli, M., Gasperini, C., Bastianello, S., Bozzao, A., Paolillo, A., Pisani, A., Galgani, S., & Pozzilli, C. (1997) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.62.3.285 · Cited by 95

The predictive value of gadolinium enhancement for long term disability in relapsing-remitting multiple sclerosis-preliminary results

Losseff, N. A., Miller, D. H., Kidd, D. P., & Thompson, A. J. (2001) · Multiple Sclerosis Journal · doi:10.1177/135245850100700105 · Cited by 31

Clinical and Magnetic Resonance Imaging Predictors of Disability in Primary and Secondary Progressive Multiple Sclerosis

Losseff, N. A., Kingsley, D. P. E., McDonald, W. I., Miller, D., & Thompson, A. J. (1996) · Multiple Sclerosis Journal · doi:10.1177/135245859600100406 · Cited by 73

Age-related gadolinium-enhancement of MRI brain lesions in multiple sclerosis

Tortorella, C., Bellacosa, A., Paolicelli, D., Fuiani, A., Monte, E. D., Simone, I. L., Giaquinto, P., Livrea, P., & Trojano, M. (2005) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2005.08.006 · Cited by 70

Resonancia magnética con gadolinio en la fase aguda de las recaídas en esclerosis múltiple

Salas, P. A. O., Silva, J. B., Lopez, L. C., Vergara, K. R., & Rovira, À. (2017) · Revista de Neurología · doi:10.33588/rn.6406.2016310 · Cited by 4